learn Rapamycin
mTOR regulator and immunosuppressant used more recently for anti-aging and hair regrowth
Search
forLearn
5 / 801 resultslearn DECAPEPTIDE-28
learn 18β-glycyrrhetinic acid
learn RU58841
a potent but unapproved and potentially problematic topical anti-androgen
learn SCUBE3
a signaling molecule from dermal papilla cells being actively researched
Research
5 / 1000+ results
research In-silico cardiac aging regulatory model including microRNA post-transcriptional regulation
Researchers created a model to understand heart aging, highlighting the role of microRNAs and identifying key genes and pathways involved.
research The role of hemp (Cannabis sativa L.) in cosmeceuticals and personal care: A systematic review
Hemp shows promise for skincare and hair care due to its therapeutic properties, but standardization and clinical evidence are needed.
research Peer Review #3 of "Inflammatory auxo-action in the stem cell division theory of cancer (v0.2)"
The reviewers suggest major revisions for clarity and inclusion of recent findings on inflammation's role in cancer.
research Identification of an Intronic Regulatory Element Necessary for Tissue-Specific Expression of Foxn1 in Thymic Epithelial Cells
A specific DNA region is crucial for Foxn1 gene expression in thymus cells but not in hair follicles.
research Alopecia areata patients show deficiency of FOXP3+CD39+ T regulatory cells and clonotypic restriction of Treg TCRβ-chain, which highlights the immunopathological aspect of the disease
Patients with Alopecia areata have fewer specific immune cells that normally regulate the immune system, which may contribute to the condition.
Community Join
5 / 169 resultscommunity Breezula 6 Month Topline Phase III Results Released
Breezula shows promising hair growth results, with up to 539% increase in hair count compared to placebo, and regulatory submissions are planned in the US and EU. Users are cautiously optimistic, noting the potential for Breezula to replace finasteride by targeting DHT without systemic effects.
community Why doesn't phase 3 of PP405 start straight away?
Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.
community Most promising cures for baldness as of May 2026
PP405 is the most promising future treatment for hair loss, aiming to reactivate dormant hair follicles. Clascoterone 5% is the most promising near-term drug, while current strategies include using finasteride or dutasteride to stabilize hair loss and minoxidil to stimulate growth.
community Breezula Phase III 12-Month Data Released by Cosmo Pharma
Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.
community What’s your views on clascoterone 5% topical solution by cosmo
Clascoterone 5% topical solution shows promise for treating male-pattern hair loss by blocking DHT at the follicle without systemic absorption, potentially offering fewer side effects than oral treatments like finasteride. While results are promising, long-term safety and effectiveness need further study, and it may serve as a starting point for developing more effective treatments.